VISION TIMELINE
*On average, people gained 6 letters at 1 month after their first treatment and gained and maintained 11 letters over 1 year on an eye chart with VABYSMO, similar to aflibercept 2 mg.
†In 2 clinical trials, VABYSMO was shown to remove excess damaging fluid in the eye, similar to aflibercept 2 mg.
‡VABYSMO was assessed in 2 clinical studies vs aflibercept 2 mg in 1891 people with DME. Both studies demonstrated non-inferiority to aflibercept 2 mg at the primary endpoint, defined as the mean change from baseline in BCVA at year 1.
§Maintained is defined as not losing 15 letters or more.
Patient compensated by Genentech. Patient experiences may vary.
TIME BETWEEN TREATMENTS
How often you receive VABYSMO depends on how your eyes respond.
Your retina specialist will choose one of the following schedules:
1. After 4 initial monthly injections, you can go 1–4 months between treatments.
2. After 6 initial monthly injections, you can go 2 months between treatments.
Although most people from the clinical trials went 3-4 months between injections, this may not be the experience of all people. Your retina specialist may evaluate your disease differently from the methods used in our trials.
#After 4 or 6 initial monthly eye injections, your doctor will choose a schedule of 1 to 4 months based on patient response. Dosing may vary.
Patient compensated by Genentech. Patient experiences may vary.
Explore our brochure for helpful information about VABYSMO and what to expect during treatment.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.